Pipitone Giuseppe, Ciusa Giacomo, Agrenzano Stefano, Di Lorenzo Francesco, Sagnelli Caterina, Cascio Antonio, Iaria Chiara
Infectious Disease Unit, ARNAS Civico-Di Cristina, 90100 Palermo, Italy.
Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy.
Healthcare (Basel). 2025 Apr 17;13(8):926. doi: 10.3390/healthcare13080926.
The aim of our study is to evaluate the impact of SARS-CoV-2 vaccination on HIV viremia in patients treated under bictegravir-based therapy. We conducted a retrospective observational study in a tertiary hospital, analyzing data from 152 patients treated with BIC/TAF/FTC between 2020 and 2022. Patients were divided into two groups: "vaccinated" (110/152) and "unvaccinated" (42/152) against SARS-CoV-2. The outcomes considered were the presence of "blips" (detectable viremia ≥ 20 copies/mL), "rebound" (viremia ≥ 50 copies/mL), and virological failures. A lower incidence of blips in the "vaccinated" group compared to the "unvaccinated" group (9.1% vs. 28.6%, = 0.002), and a reduced risk of blips in the vaccinated group (OR 3.8, 95% CI 1.4-9.8) were noticed. The rebound rate was lower in the vaccinated group compared to non-vaccinated, with a statistically significant difference (respectively, 2.7% vs. 11.9%, = 0.037). our data suggest that SARS-CoV-2 vaccination may stimulate an immune response that enhances CD4+ and CD8+ cell function, contributing to a reduction in the number of blips and maintaining good viro-immunological control in patients with HIV, supporting the importance of vaccination in this population.
我们研究的目的是评估严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗接种对接受基于比克替拉韦治疗的患者体内艾滋病毒病毒血症的影响。我们在一家三级医院进行了一项回顾性观察研究，分析了2020年至2022年期间152例接受比克替拉韦/替诺福韦艾拉酚胺/恩曲他滨（BIC/TAF/FTC）治疗的患者的数据。患者被分为两组：针对SARS-CoV-2的“接种疫苗组”（110/152）和“未接种疫苗组”（42/152）。所考虑的结果包括“病毒载量波动”（可检测到的病毒血症≥20拷贝/毫升）、“病毒载量反弹”（病毒血症≥50拷贝/毫升）和病毒学失败。与“未接种疫苗组”相比，“接种疫苗组”的病毒载量波动发生率较低（9.1%对28.6%，P = 0.002），并且接种疫苗组出现病毒载量波动的风险降低（比值比3.8，95%置信区间1.4 - 9.8）。接种疫苗组的病毒载量反弹率低于未接种疫苗组，差异具有统计学意义（分别为2.7%对11.9%，P = 0.037）。我们的数据表明，SARS-CoV-2疫苗接种可能刺激免疫反应，增强CD4 +和CD8 +细胞功能，有助于减少病毒载量波动的次数，并在艾滋病毒患者中维持良好的病毒免疫控制，支持在这一人群中进行疫苗接种的重要性。
